XLO – xilio therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript [Seeking Alpha]
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Form 4 Xilio Therapeutics, Inc. For: Nov 26 Filed by: GILEAD SCIENCES, INC.
Form S-8 Xilio Therapeutics, Inc.
Form 4 Xilio Therapeutics, Inc. For: Nov 21 Filed by: Brennan Kevin M.
Form 4 Xilio Therapeutics, Inc. For: Nov 21 Filed by: Russo Rene
Form 4 Xilio Therapeutics, Inc. For: Nov 21 Filed by: Luptakova Katarina
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.